Shares of Second Sight Medical Continue Showing Strength Following Wednesday's IPO

Shares of

surged more than 100 percent on its first day of trading on Wednesday and the buying frenzy carried over in to Thursday's trading action. The company develops, manufactures and markets implantable prosthetic devices that could potentially restore functional vision to patients that suffer from outer retinal degenerations such as Retinitis Pigmentosa. Al Mann, the nearly 90-year old billionaire behind other companies including

sits on Second Sight's Board of Directors. In total, Mann has been involved with 17 separate companies. The company originally priced 3.5 million shares at $9 for its initial public offering and began trading for the first time at $17 shortly after noon on Wednesday. Shares were surging more than 15 percent in Thursday's morning trading session, reaching as high as $23.85.